A Phase 2 Study of Biomarker-Modulated PSMA Theranostics
Latest Information Update: 23 May 2025
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms Low PSMA SUV Boost (LPS-Boost)
Most Recent Events
- 06 Apr 2025 Planned initiation date (estimated date of first participant enrollment) changed from 1 Apr 2025 to 1 May 2025.
- 07 Mar 2025 Planned initiation date changed from 1 Mar 2025 to 1 Apr 2025.
- 06 Feb 2025 Status changed from not yet recruiting to recruiting.